Skip to content

Study · Observational study · n = 88 · 2023

3 results

[Cerebrolysin Treatment Reduces the Risk of Mild Cognitive Decline to Dementia in 1st-Degree Relatives of Alzheimer's Patients: A Prospective Comparative Study].

Selezneva ND, Gavrilova SI

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2023Cited by 4 (Europe PMC)

PMID37655416 (opens in a new tab)DOI10.17116/jnevro202312308190 (opens in a new tab)PepBankPUB-37655416
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In relatives of Alzheimer's patients with aMCI, Cerebrolysin treatment was linked to no dementia conversions, while conversions occurred in untreated relatives.

    In plain wordsIn relatives with mild cognitive decline, Cerebrolysin treatment was linked to no dementia conversions, compared with conversions in untreated relatives.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseConversion from aMCI to dementia
    Study

    n = 88

    Comparator
    Untreated relatives
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    20 ml · intravenousAs given in this study (human).

    Measurements

    Annual conversion from aMCI to dementia
    9.5%
    comparison group (untreated)

    Source sentences

    Summary
    The annual conversion from aMCI to dementia due to probable AD was 9.5% only in the comparison group.
    2 context sentences
    Summary · context
    The absence of cases of aMCI conversion to dementia in the treated patients for 2.5 years of observation can serve as confirmation of a disease-modifying effect in Cerebrolysin.
    Summary · context
    The cohort included 88 first-degree relatives of BA patients with aMCI syndrome aged 50 to 82 years (mean age 65.0±9.9 years) of which 46 people received course therapy with Cerebrolysin and 42 people were not treated.
  2. 02HumanObservational studyEfficacy outcome

    In relatives of Alzheimer's patients with aMCI, Cerebrolysin treatment was linked to pronounced or moderate CGI-I improvement in 95.7% of cases.

    In plain wordsIn relatives with mild cognitive decline, Cerebrolysin treatment was linked to pronounced or moderate CGI-I improvement in 95.7% of cases.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCGI-I improvement responders
    Study

    n = 46

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    20 ml · intravenous · 3 annual courses of 20 intravenous infusions eachAs given in this study (human).

    Measurements

    Pronounced or moderate improvement
    95.7%
    CGI-I; end of third therapy course

    Source sentences

    Summary
    In the therapeutic group, according to the CGI-I scale, by the end of the 3rd course of therapy, in 95.7% of cases, a pronounced or moderate improvement was achieved after each of the courses on all scales and tests.
    2 context sentences
    Summary · context
    The cohort included 88 first-degree relatives of BA patients with aMCI syndrome aged 50 to 82 years (mean age 65.0±9.9 years) of which 46 people received course therapy with Cerebrolysin and 42 people were not treated.
    Summary · context
    Conducted annual course therapy with Cerebrolysin (a total of 3 courses of infusion therapy: for a course of 20 intravenous infusions of 20 ml of Cerebrolysin in 100 ml of isotonic saline) followed by a follow-up study after 3 months after the end of the therapeutic period.
  3. 03HumanObservational studyEfficacy outcome

    In relatives of Alzheimer's patients with aMCI, Cerebrolysin treatment was linked to significantly improved initial mean group scores by treatment end.

    In plain wordsIn relatives with mild cognitive decline, Cerebrolysin treatment was linked to improved mean cognitive scores compared with initial scores.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseMean cognitive scores at end of treatment
    Study

    n = 46

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    20 ml · intravenousAs given in this study (human).

    Measurements

    P value for improvement of initial average group scores
    < 0.05
    Cerebrolysin group; all scales and tests; after each therapy course versus initial scores

    Source sentences

    Summary
    In this group, by the end of the therapeutic period, a significant improvement in the initial mean group scores was established.
    Summary
    According to the all scales and tests, a significant improvement of the initial average group scores was found after each course of therapy (p<0.05).
    2 context sentences
    Summary · context
    The cohort included 88 first-degree relatives of BA patients with aMCI syndrome aged 50 to 82 years (mean age 65.0±9.9 years) of which 46 people received course therapy with Cerebrolysin and 42 people were not treated.
    Summary · context
    Conducted annual course therapy with Cerebrolysin (a total of 3 courses of infusion therapy: for a course of 20 intravenous infusions of 20 ml of Cerebrolysin in 100 ml of isotonic saline) followed by a follow-up study after 3 months after the end of the therapeutic period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.